Inhibitory capacity of Chloroquine against SARS-COV-2 by effective binding with Angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies
Baildya et al.,
Inhibitory capacity of Chloroquine against SARS-COV-2 by effective binding with Angiotensin converting..,
Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.129891
Molecular docking study of 16 drugs showing CQ had the highest binding affinity with ACE2, and molecular dynamics study of the docked CQ-ACE2 structure. Authors conclude that CQ binds reasonably strongly with ACE2 and the stable ACE2-CQ may prevent further binding of ACE2 with the SARS-CoV-2 spike protein.
Baildya et al., 7 Jan 2021, peer-reviewed, 3 authors.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: Journal of Molecular Structure 1230 (2021) 129891
Contents lists available at ScienceDirect
Journal of Molecular Structure
journal homepage: www.elsevier.com/locate/molstr
Inhibitory capacity of chloroquine against SARS-COV-2 by effective
binding with angiotensin converting enzyme-2 receptor: An insight
from molecular docking and MD-simulation studies
Nabajyoti Baildya a,∗, Narendra Nath Ghosh b, Asoke P. Chattopadhyay a
a
b
Department of Chemistry, University of Kalyani, Kalyani 741235, India
Department of Chemistry, University of Gour Banga, Mokdumpur, Malda, 732103, India
a r t i c l e
i n f o
Article history:
Received 22 June 2020
Revised 22 August 2020
Accepted 4 January 2021
Available online 7 January 2021
Keywords:
Chloroquine (CLQ)
Angiotensin converting enzyme 2 (ACE2)
protein
Molecular docking
MD-simulation
a b s t r a c t
The main binding site for SARS-COV-2 spike protein in human body is human Angiotensin converting
enzyme 2 (ACE2) protein receptor. Herein we present the effect of chloroquine (CLQ) on human ACE2
receptor. Molecular docking studies showed that chloroquine have a docking score is quite high compare
to other well known drugs. Furthermore, molecular dynamics (MD) studies with CLQ docked ACE2 results
in large fluctuations on RMSD up to 2.3 ns, indicating conformational and rotational changes due to the
presence of drug molecule in the ACE2 moiety. Analysis of results showed that CLQ can effect the conformation of human ACE2 receptor. We believed that this work will help researchers to understand better
the effect of CLQ on ACE2.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit